Glenmark Launches Covid-19 Drug Favipiravir and announced the antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
The Mumbai-based Glenmark Pharmaceuticals drug firm had received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
Favipiravir, sold under the brand name Avigan or Abigan, is an antiviral medication used to treat influenza in Japan.
Also Read – Do vaccines against pneumonia protect against new coronavirus ?
“This approval comes at a time when cases in India are spiraling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
Probably, FabiFlu may help in curing the Coronavirus in India.
